Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,013 Mln
P/E Ratio
--
P/B Ratio
2.53
Industry P/E
--
Debt to Equity
0
ROE
-0.78 %
ROCE
-76 %
Div. Yield
0 %
Book Value
3.82
EPS
-3.5
CFO
$-371.23 Mln
EBITDA
$-433.92 Mln
Net Profit
$-457.43 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
89bio (ETNB)
| -11.25 | -24.15 | -2.66 | -19.11 | 37.49 | -23.24 | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
89bio (ETNB)
| -29.79 | -12.25 | -2.60 | -46.37 | -7.30 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of... fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California. Read more
CEO & Director
Mr. Rohan Palekar
CEO & Director
Mr. Rohan Palekar
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of 89bio Inc (ETNB) stood at $ 479 Mln as on 31-Dec-24
The share price of 89bio Inc (ETNB) is $6.94 (NASDAQ) as of 25-Apr-2025 16:00 EDT. 89bio Inc (ETNB) has given a return of 37.49% in the last 3 years.
89bio Inc (ETNB) has a market capitalisation of $ 1,013 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of 89bio Inc (ETNB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 89bio Inc (ETNB) and enter the required number of quantities and click on buy to purchase the shares of 89bio Inc (ETNB).
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
The CEO & director of Mr. Rohan Palekar. is 89bio Inc (ETNB), and CFO & Sr. VP is Mr. Rohan Palekar.
There is no promoter pledging in 89bio Inc (ETNB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| 89bio Inc. (ETNB) | Ratios |
|---|---|
|
Return on equity(%)
|
-78.34
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of 89bio Inc (ETNB) was $0 Mln.
$0.04
(
